| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5725897 | Current Problems in Diagnostic Radiology | 2017 | 12 Pages |
Abstract
18F-fluorodeoxryglucose (18F-FDG) PET/CT imaging is routinely performed in the evaluation of patients with known or suspected thoracic malignancy. Indications for its use include staging of malignancy, assessment of response to therapy, evaluation of suspected disease recurrence, and evaluation of a solitary pulmonary nodule. In this article, we will discuss specific technical artifacts and also review potential pitfalls in the interpretation of PET/CT in thoracic malignancies including normal variations in physiologic uptake of FDG, benign conditions (such as infection, inflammation, posttreatment changes, and iatrogenic factors) that can result in increased FDG uptake, and malignancies that demonstrate scarce to no FDG uptake.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Girish S. MD, Brett W. MD, Chitra MD, Marcelo F. MD, Carol C. MD, Edith M. MD, Osama R. PhD, Mylene T. MD,